In November 2018, the American Heart Association (AHA) updated Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Rather than a comprehensive revision of the 2015 edition guidelines, the 2018 AHA guidelines update was updated again according to the rule " the update of the guideline is whenever new evidence is available”, providing the evidence review and treatment recommendation for antiarrhythmic drug therapy in pediatric shock-refractory ventricular fibrillation/pulseless ventricular tachycardia cardiac arrest. The Pediatric Task Force of the International Liaison Committee on Resuscitation updated the guideline, reaffirming the 2015 pediatric advanced life support guideline recommendation that either lidocaine or amiodarone may be used to treat pediatric patients with shock-refractory ventricular fibrillation or pulseless ventricular tachycardia.
Citation: ZHOU Yan, LI Xihong. Interpretation of the 2018 Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care: pediatric advanced life support. West China Medical Journal, 2018, 33(11): 1356-1358. doi: 10.7507/1002-0179.201811066 Copy
-
Previous Article
Interpretation of the 2018 Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care: The Use of Antiarrhythmic Drugs During Advanced Cardiovascular Life Support and Immediately after Restoration of Spontaneous Circulation in Patients with Cardiac Arrest -
Next Article
Clinical features and genetic study of three patients with leber congenital amaurosis